Monday’s non-tech strength is coming from three very different catalysts. Boeing has the most company-specific evidence, airlines have the strongest macro tailwind, and Bristol Myers Squibb has the least dependable setup because its move depends on an unconfirmed takeover report.

The practical distinction is durability: an operating recovery can survive a quiet news day, an oil-relief trade can reverse with one geopolitical headline, and a merger premium can disappear if talks fail.

Market snapshot

Observed Monday, August 3, 2026, at approximately 9:35 a.m. ET / 2:35 p.m. BST. Prices and percentages are intraday and may change before the close.

  • The S&P 500 was up 0.6%, the Dow was up 1.2%, and the Nasdaq Composite was up 0.6%.
  • Brent crude was down 4.9% to $83.65 a barrel as immediate U.S.–Iran escalation fears eased.
  • The 10-year Treasury yield fell to 4.68% from 4.75% on Friday.
  • United Airlines and American Airlines were each up more than 5%, while Boeing rose roughly 4% and Bristol Myers Squibb gained about 4%–5%.

This is a broad relief session, but not every green stock has the same quality of momentum.

1. Boeing: the cleanest company-specific setup

Boeing rose after BNP Paribas made a rare two-step upgrade from underperform to outperform. The upgrade follows improving operating evidence rather than a purely macro-driven bounce.

Boeing delivered 171 commercial aircraft in the second quarter, including 129 737s, and reported a surprise $631 million of free cash flow despite continuing losses. Its total backlog remains exceptionally large, while management is working to raise 737 and 787 production.

Catalyst: higher aircraft deliveries, a controlled production ramp and further improvement in cash generation.

Evidence: the latest delivery count and positive free cash flow give investors measurable signs that the recovery is progressing.

Main risk: Boeing is still in a multi-year operational turnaround. Safety, quality, supplier constraints, certification delays or another production setback could overwhelm analyst optimism.

Invalidation condition: the momentum case weakens if the stock gives back the upgrade gap and closes below Friday’s level, especially if future delivery data or cash flow deteriorate.

2. Airlines: powerful momentum that still belongs to oil

United Airlines and American Airlines rose more than 5% as crude prices dropped sharply. Lower oil can reduce expected jet-fuel expense and ease inflation pressure on travel demand.

This is credible relative strength, but it is not yet evidence of a company-specific earnings upgrade. The same group has repeatedly moved in the opposite direction when Middle East tensions pushed oil higher.

Catalyst: Brent remaining near or below the mid-$80s, stable ticket demand and no renewed disruption around the Strait of Hormuz.

Evidence: airlines are outperforming the broad indexes while oil falls, showing that investors are rapidly repricing near-term fuel risk.

Main risk: the geopolitical situation is unresolved. Iran denied that a final agreement had been reached, so crude and airline shares can reverse quickly.

Invalidation condition: the sector gives back Monday’s gains even while Brent remains below roughly $85. That would suggest short covering rather than a durable improvement in earnings expectations.

3. Bristol Myers Squibb: a deal premium, not an operating breakout

Bristol Myers Squibb gained after reports that AstraZeneca had discussed a combination that could create a pharmaceutical company worth roughly $400 billion. AstraZeneca shares fell, while Bristol Myers rose as investors priced a possible acquisition premium.

Both companies declined to comment, and analysts immediately raised questions about antitrust risk, overlapping oncology portfolios and whether such a large transaction would improve AstraZeneca’s growth profile.

Catalyst: confirmation of formal negotiations and terms that offer Bristol Myers shareholders a meaningful premium.

Evidence: the stock reaction is consistent with investors treating Bristol Myers as the potential target rather than rewarding a fresh operating result.

Main risk: the report may not lead to a transaction. Even confirmed talks could fail because of price, financing, regulation or strategic disagreement.

Invalidation condition: either company denies active talks, credible reporting says negotiations have ended, or Bristol Myers loses the pre-report price level.

Which momentum is most durable?

SelectionWhat is driving itEvidence qualityMain dependency
BoeingUpgrade plus improving deliveries and cash flowStrongest of the threeExecution and production quality
AirlinesSharp oil-price declineClear but macro-drivenOil and geopolitics
Bristol Myers SquibbReported AstraZeneca merger talksEvent-driven and unconfirmedA deal actually progressing

Boeing currently has the best blend of price strength and company-specific evidence. Airlines have the strongest immediate move but remain an oil trade. Bristol Myers may deliver the largest one-off premium, but it also has the clearest binary risk.

Bottom line

Momentum is more useful when its cause can be measured. For Boeing, watch deliveries, production and cash flow. For airlines, watch Brent rather than the index alone. For Bristol Myers, treat the rally as merger speculation until the companies provide confirmation.

A green screen does not make these setups equivalent. The catalyst determines how quickly the thesis can break.

Educational disclaimer: This article is for informational and educational purposes only. It is not financial advice, investment research or a recommendation to buy or sell any security. Intraday prices can change quickly, and event-driven stocks can gap beyond expected risk levels.

Sources

MarketMomentumInvestingBoeingAirlineStocksHealthcareStocks
Written and reviewed by /lico

Just writing down my thoughts, interests, and the things I learn along the way.